Industry Delighted By ‘Fixed’ USMCA
Removes Biologic Exclusivity Requirement And Allows Incentives For Generics
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
You may also be interested in...
Departing BGMA leader Warwick Smith highlights successes in the UK off-patent industry’s response to the COVID-19 pandemic but offers unambiguous criticism of Brexit in the concluding part of an exclusive interview with Generics Bulletin.
Laying out the 2021 outlook for US generics and biosimilars, AAM president and CEO Dan Leonard has urged US president-elect Joe Biden and lawmakers in the US Congress to act to maximize savings and access to medicines.
Global free trade agreements are having a detrimental effect on savings that can be achieved by using generics and biosimilars across healthcare systems worldwide, according to a new IQVIA report hosted by the IGBA.